People: Navidea Biopharmaceuticals Inc (NAVB.A)

Summary

Name	Age	Since	Current Position
Gordon Troup	59	2011	Independent Chairman of the Board
Thomas Tulip	60	2013	President, Chief Business Officer
Mark Pykett	49	2013	Chief Executive Officer, Director
Brent Larson	49	2010	Chief Financial Officer, Senior Vice President, Treasurer, Secretary
Frederick Cope	66	2010	SVP - Pharmaceutical Research and Clinical Development
William Regan	61	2012	Senior Vice President - Global Regulatory Strategy
Cornelia Reininger	60	2012	Senior Vice President, Chief Medical Officer
Rodger Brown	61	2000	Vice President - Regulatory Affairs and Quality Assurance
Eric Rowinsky	56	2010	Director
Peter Drake	59	2011	Independent Director
Brendan Ford	54	2010	Independent Director
Jess Jones	34	2011	Independent Director

» Insider Trading

Biographies

Name	Description
Gordon Troup	Mr. Gordon A. Troup is Independent Chairman of the Board of Navidea Biopharmaceuticals Inc. Mr. Troup has served as a director of Navidea since July 2008. Mr. Troup served as President of the Nuclear Pharmacy Services business at Cardinal Health, Inc. (Cardinal Health), a multinational medical products and services company, from January 2003 until his retirement in December 2007. Mr. Troup joined Cardinal Health in 1990 and was appointed Group President of Pharmaceutical Distribution and Specialty Distribution Services in 1999. Prior to joining Cardinal Health, Mr. Troup was employed for 10 years by American Hospital Supply Corporation and 3 years by Zellerbach Paper, a Mead Company. Mr. Troup has a B.S. degree in Business Management from San Diego State University.
Thomas Tulip	Dr. Thomas H. Tulip, Ph.D. has been appointed as President, Chief Business Officer of Navidea Biopharmaceuticals Inc., effective May 1, 2013. Prior to his appointment as President and Chief Business Officer, Dr. Tulip had served as Executive Vice President and Chief Business Officer of the Company since June 2011. Dr. Tulip has held senior leadership positions at Alseres Pharmaceuticals, Lantheus Medical Imaging, Bristol Myers Squibb (“BMS”) and DuPont, where his roles spanned product discovery and development, business and technology planning, brand and alliance management and international business management. Most recently, as President, Alseres Molecular Imaging, Dr. Tulip led efforts to develop markets for a Phase III neuroimaging agent. While at DuPont and BMS prior to Alseres, he was instrumental in the development, commercialization and international management of a nuclear cardiology franchise, built the BMS Medical Imaging international business, and led planning activities for innovative PET tracers at Lantheus/BMS. Dr. Tulip earned a B.S. from University of Vermont, and an M.S. and Ph.D. from Northwestern University. He was a visiting scholar at Osaka University and served as adjunct professor at Northeastern University. Dr. Tulip serves on the board of directors of the Medical Imaging Technology Association and leads its PET Working Group in the Molecular Imaging Section. He was recently Chairperson of the Institute for Molecular Technologies and held numerous leadership positions there. He served on the Board of the Academy of Molecular Imaging, including as its Treasurer. Dr. Tulip was Chairperson for the Society of Nuclear Medicine Corporate Advisory Board and has been active in a number of Council on Radionuclides and Radiopharmaceuticals committees, now serving on its Board of Directors.
Mark Pykett	Dr. Mark J. Pykett is Chief Executive Officer, Director of Navidea Biopharmaceuticals Inc. Dr. Pykett has served as a director of the Company since August 2011 and as President and Chief Executive Officer of Navidea since April 2011. Prior to joining Navidea as Executive Vice President and Chief Development Officer in November 2010, Dr. Pykett served as Founding CEO of Talaris Advisors LLC, a strategic drug-development company serving the biotech industry, from 2009 to November 2010. Prior to Talaris, Dr. Pykett was President and Chief Operating Officer of Alseres Pharmaceuticals, Inc. (formerly Boston Life Sciences, Inc.), President and a Director of CyGenics, President of Cordlife, and President and Chief Executive Officer and a director of Cytomatrix. Dr. Pykett has also served on the boards of directors of several public, private and not-for-profit organizations. Dr. Pykett also was an adjunct lecturer in cancer biology at Harvard University’s School of Public Health and served on Northeastern University’s Center for Enterprise Growth Corporate Advisory Board. He holds Ph.D. in molecular biology from the University of Pennsylvania, and an M.B.A., Beta Gamma Sigma, from Northeastern University. In addition, Dr. Pykett completed post-doctoral fellowships at the University of Pennsylvania and Harvard University.
Brent Larson	Mr. Brent L. Larson is Chief Financial Officer, Senior Vice President, Treasurer, Secretary of Navidea Biopharmaceuticals Inc. He has served as Senior Vice President of the Company since July 2010, as Chief Financial Officer and Treasurer since February 1999 and as Secretary since 2003. Prior to that, Mr. Larson served as Vice President, Finance from July 1998 to July 2010 and as Controller from July 1996 to June 1998. Before joining the Company, Mr. Larson was employed by Price Waterhouse LLP. Mr. Larson has a B.B.A. degree in accounting from Iowa State University of Science and Technology and is a Certified Public Accountant.
Frederick Cope	Dr. Frederick O. Cope is Senior Vice President - Pharmaceutical Research and Clinical Development of Navidea Biopharmaceuticals Inc. He was Vice President, Pharmaceutical Research and Clinical Development from February 2009 to July 2010. Prior to accepting his position with Navidea, Dr. Cope served as the Assistant Director for Research and Head of Program Research Development for The Ohio State University Comprehensive Cancer Center, The James Cancer Hospital and The Richard J. Solove Research Institute, from April 2001 to February 2009. Dr. Cope served as head of the Cancer and AIDS product development and commercialization program for the ROSS/Abbott Laboratories division for 10 years, and head of human and veterinary vaccine production and improvement group for Wyeth Laboratories for seven years. Dr. Cope served a fellowship in oncology at the McArdle Laboratory for Cancer Research at the University of Wisconsin and the honored scientist in residence at the National Cancer Center Research Institute in Tokyo; he is the recipient of the Ernst W. Volwiler Research Award. Dr. Cope is active in a number of professional and scientific organizations such as serving as an editorial reviewer for several professional journals, and as an advisor/director to the research program of Roswell Park Memorial Cancer Center. Dr. Cope received his B.Sc. from the Delaware Valley College of Science and Agriculture, his M.S. from Millersville University of Pennsylvania and his Ph.D. from the University of Connecticut with full honors.
William Regan	Mr. William J. Regan is Senior Vice President - Global Regulatory Strategy of Navidea Biopharmaceuticals Inc. Prior to accepting his position with Navidea, Mr. Regan served as a consultant to Navidea from July 2011 to September 2012. As Principal of Regan Advisory Services (RAS) from September 2006 to September 2012, Mr. Regan consulted on all aspects of regulatory affairs within pharmaceutical, biotechnology and diagnostic imaging businesses, including PET diagnostic agents (cardiovascular, neurology, and oncology), contrast agents, and radiopharmaceuticals. Previous to RAS, Mr. Regan held roles of increasing responsibility in radiopharmaceutical manufacturing, quality assurance, pharmaceutical technology and regulatory affairs at Bristol-Myers Squibb (BMS). From September 2001 to August 2006, he served as global regulatory head for BMS’ Medical Imaging business where he was responsible for all regulatory aspects of the company’s in-market and pipeline products and led regulatory actions resulting in product approvals. Mr. Regan has been an active member in the Society of Nuclear Medicine, Council on Radionuclides and Radiopharmaceuticals (CORAR), and Medical Imaging and Technology Alliance, and formerly served as the industry chair of the Regulatory and Clinical Practice committee on behalf of CORAR. Mr. Regan holds a B.A. in Chemistry from Rutgers University.
Cornelia Reininger	Dr. Cornelia Reininger, M.D., Ph.D., is Senior Vice President, Chief Medical Officer of Navidea Biopharmaceuticals, Inc. Dr. Reininger joins Navidea from Bayer Healthcare Pharmaceuticals, where she was Senior Director of Clinical Research and Global Clinical Leader for its Alzheimer’s development programs, spearheading clinical development from Phase 1 through Phase 3 and the registration filings of the Company’s PET neuroimaging agent florbetaben. Previously, Dr. Reininger served in roles of increasing responsibility with the global medical organizations of GE Healthcare and Amersham Health – Diagnostic Imaging and played a central role in the development of GE Healthcare’s DaTscan imaging agent for the diagnosis of Parkinson’s disease and its expansion into the indication for dementia with Lewy Bodies. Dr. Reininger holds an Associate Professor of Surgery and External Lecturer position at Ludwig Maximillian University (LMU) in Munich, Germany, where she completed her medical education and residency in general and vascular surgery. During her residency, she was on staff at the LMU Downtown Surgical Hospital and Outpatient Clinic, rotating as Chief Resident in vascular surgery and the intensive care unit. She later became the head of the hospital’s thrombosis research laboratory.
Rodger Brown	Mr. Rodger A. Brown is no longer Vice President - Regulatory Affairs and Quality Assurance of Navidea Biopharmaceuticals Inc. From July 1998 through November 2000, Mr. Brown served as Director, Regulatory Affairs and Quality Assurance. Prior to joining Navidea, Mr. Brown served as Director of Regulatory Affairs and/ Quality Assurance for Biocore Medical Technologies, Inc. from April 1997 to April 1998. From 1981 through 1996, Mr. Brown served as Director, Regulatory Affairs/Quality Assurance for E for M Corporation, a subsidiary of Marquette Electronics, Inc.
Eric Rowinsky	Dr. Eric K. Rowinsky is Director of Navidea Biopharmaceuticals Inc. In 2012, Dr. Rowinsky began serving as the Head of Research and Development, Chief Medical Officer, and Executive Vice President of Stemline Therapeutics, Inc., a discovery- and development-stage biotechnology company. In 2010, Dr. Rowinsky also co-founded Primrose Therapeutics, a start-up biotechnology company which was acquired in September 2011, and was a consultant in the area of new cancer drug development. From 2005 to December 2009, he served as the Chief Medical Officer and Executive Vice President of Clinical Development, Medical Affairs and Regulatory Affairs of ImClone Systems Incorporated, a life sciences company, and was a principal consultant to the Lilly-ImClone Oncology Business Unit in 2010. Prior to that, Dr. Rowinsky held several positions at the Cancer Therapy & Research Center’s Institute of Drug Development, including Director of the Institute, Director of Clinical Research and SBC Endowed Chair for Early Drug Development, and concurrently served as Clinical Professor of Medicine in the Division of Medical Oncology at the University of Texas Health Science Center at San Antonio. Dr. Rowinsky was an Associate Professor of Oncology at the Johns Hopkins University School of Medicine and on active staff at the Johns Hopkins School of Medicine from 1987 to 1996. Dr. Rowinsky is a member of the boards of directors of Biogen Idec, Inc. and of Coronado Biosciences, Inc., publicly-held life sciences companies. Dr. Rowinsky serves on the Science and Research and Compensation Committees at Biogen Idec. During the past five years, Dr. Rowinsky has also served as a director of Tapestry Pharmaceuticals, Inc. and ADVENTRX Pharmaceuticals, Inc., publicly-held life sciences companies.
Peter Drake	Dr. Peter F. Drake is Independent Director of Navidea Biopharmaceuticals Inc. Dr. Drake began his career as a biotechnology analyst at Kidder, Peabody and Co. where he was a partner and head of the Healthcare Research Group. In 1988, Dr. Drake co-founded Vector Securities International, an investment banking firm specializing in the life sciences industry, where he was Executive Vice President and Director of Research. In 1993, Dr. Drake co-founded Vector Fund Management, a life sciences venture fund, and Deerfield Management, a healthcare hedge fund. In 1999, Vector Securities International was purchased by Prudential Securities, where he was a Managing Director and Head of Healthcare Research. Dr. Drake has served on the board of directors of Penwest Pharmaceuticals, a publicly traded specialty pharmaceutical company, which was purchased in 2010. He currently is a board member of Trustmark Insurance, a mutual insurance company; Rodman and Renshaw, a publicly traded investment banking firm; and Cortex Pharmaceuticals, a public neuroscience company. Dr. Drake received his undergraduate degree from Bowdoin College, and his Ph.D. in neurobiology and biochemistry from Bryn Mawr College.
Brendan Ford	Mr. Brendan A. Ford is Independent Director of Navidea Biopharmaceuticals Inc. Since 2007, Mr. Ford has been a partner in Talisman Capital Partners, a private investment partnership focusing on middle-market companies. From 1991 through 2007, Mr. Ford served in executive positions including Executive Vice President, Business Development and Corporate Strategy with Cardinal Health, Inc., primarily in capacities related to mergers, acquisitions and related strategic activities, and was in $19 billion in acquisition and disposition transactions for Cardinal. Prior to his service with Cardinal Health, Mr. Ford practiced law with Baker and Hostetler from 1986 to 1991. From 1980 to 1983, Mr. Ford was employed by Touche Ross LLP as a certified public accountant. Mr. Ford has a B.S. in Business from Miami University, and a J.D. from The Ohio State University.
Jess Jones	Dr. Jess Emery Jones is Independent Director of Navidea Biopharmaceuticals Inc. He is currently the Chief Executive Officer of AngioLight, Inc. (formerly CorNova, Inc.). In addition to AngioLight, Dr. Jones is the Chief Executive Officer of NewCardio, Inc. Dr. Jones is on the boards of directors of AngioLight, NewCardio, and NovaRay Inc. From October 2006 to January 2011, Dr. Jones worked with Vision Capital Advisors, LLC in New York City as the Director of Healthcare Investing, analyzing investment opportunities in the biotech, pharmaceutical, medical technology, and medical services fields, and assisted companies in the implementation of their business plans. From 2001 to 2007, Dr. Jones attended Columbia College of Physicians & Surgeons in New York City, where he received his medical degree in May 2007. In 2005, while attending Columbia Medical School in New York City, Dr. Jones was awarded an American Heart Association - Medical Student Research Fellowship to study post-stroke inflammatory mediators in the Department of Neurosurgery. Additionally, Dr. Jones earned a B.A. degree from the University of Utah in 2001 and an M.B.A. from Columbia Business School in May 2007.

Basic Compensation

Name	Fiscal Year Total
Gordon Troup	--
Thomas Tulip	713,424
Mark Pykett	2,044,580
Brent Larson	495,562
Frederick Cope	581,925
William Regan	--
Cornelia Reininger	--
Rodger Brown	344,124
Eric Rowinsky	--
Peter Drake	--
Brendan Ford	--
Jess Jones	--

As Of 30 Dec 2012

Options Compensation

Name	Options	Value
Gordon Troup	0	0
Thomas Tulip	0	0
Mark Pykett	0	0
Brent Larson	627,200	318,300
Frederick Cope	0	0
William Regan	0	0
Cornelia Reininger	0	0
Rodger Brown	604,500	496,100
Eric Rowinsky	0	0
Peter Drake	0	0
Brendan Ford	0	0
Jess Jones	0	0

Insider Trading

Name	Shares Traded	Price
TULIP THOMAS H	17,500	$2.82
TROUP GORDON A	7,000	$2.70
FORD BRENDAN A	5,000	$2.71
PYKETT MARK JEROME	1,850	$2.70
REGAN WILLIAM J	5,000	$2.71
PYKETT MARK JEROME	175,000	$0.00
FORD BRENDAN A	30,000	$0.00
LARSON BRENT L	42,821	$3.16
ROWINSKY ERIC K	30,000	$0.00
BROWN RODGER A	45,000	$0.00
BROWN RODGER A	16,194	$3.16
PYKETT MARK JEROME	58,302	$3.16
TROUP GORDON A	30,000	$0.00
COPE FREDERICK O	42,686	$3.16
COPE FREDERICK O	125,000	$0.00
LARSON BRENT L	125,000	$0.00
JONES JESS EMORY	12,250	$0.00
DRAKE PETER F	12,250	$0.00
TROUP GORDON A	12,250	$0.00
FORD BRENDAN A	12,250	$0.00
ROWINSKY ERIC K	12,250	$0.00
PYKETT MARK JEROME	34,074	$3.08
PYKETT MARK JEROME	34,074	$3.08
PLATINUM MONTAUR LIFE SCIENCES L L C	3,001,860	$2.58
PLATINUM MONTAUR LIFE SCIENCES L L C	37,030	$2.56

» Full list on Insider Trading

People: Navidea Biopharmaceuticals Inc (NAVB.A)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: